pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors

<figref>image 1</figref>

15

25

35

45

55

Pyrrolo [2,3-b] pyridine-4-yl-amines and pyrrolo [2,3-b] pyrimidine-4-yl-amines as Janus kinase inhibitors

Description

FIELD OF THE INVENTION

The present invention provides pyrrolo [2,3-b] pyridine-4-yl amines and pyrrolo [2,3-b] pyrimidine-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of related diseases with the activity of Janus kinases including, for example, diseases related to immunity, skin disorders and cancer.

BACKGROUND OF THE INVENTION

The immune system responds to injuries and threats of pathogens. Cytokines are low molecular weight polypeptides or glycoproteins that stimulate biological responses in virtually all cell types. For example, cytokines regulate many of the pathways involved in the host's inflammatory response to sepsis. Cytokines influence cell differentiation, proliferation and activation, and can modulate both proinflammatory and anti-inflammatory responses to allow the host to react appropriately to pathogens.

The binding of a cytokine to its cell surface receptor initiates intracellular signaling cascades that transduce the extracellular signal to the nucleus, eventually leading to changes in gene expression. The pathway involving the Janus family of protein tyrosine kinase kinases (JAKs) and Signal Transducers and Transcription Activators (STATs) is involved in signaling a wide range of cytokines. Generally, cytokine receptors do not have intrinsic tyrosine kinase activity, and therefore require receptor-associated kinases to propagate the phosphorylation cascade. JAKs fulfill this function. Cytokines bind to their receptors, causing dimerization of the receptor, and this allows JAKs to phosphorylate with each other as well as specific tyrosine motifs within cytokine receptors. STATs that recognize these phosphotyrosine motifs are recruited to the recipient, and are then activated by a tyrosine phosphorylation event dependent on JAKs. At the time of activation, STATs dissociate from receptors, dimerize and translocate the nucleus to bind to specific DNA sites and alter transcription (Scott, MJ, CJ Godshall, et al. (2002). "Jaks, STATs, Cytokines, and Sepsis. "Clin Diagn Lab Immunol 9 (6): 11539).

The JAK family plays a role in the cytokine-dependent regulation of proliferation and function of cells involved in the immune response. Currently, there are four members of the JAK family known mammals: JAK1 (also known as Janus kinase-1), JAK2 (also known as Janus kinase-2), JAK3 (also known as Janus kinase, leukocyte; JAKL; L-JAK and Janus kinase-3) and TYK2 (also known as protein tyrosine kinase 2). JAK proteins vary in size from 120 to 140 kDA and comprise seven conserved JAL (JH) homology domains; one of these is a functional catalytic kinase domain, and the other is a pseudokinase domain that potentially serves as a regulatory function and / or serves as a coupling site for STATs (Scott, Godshall et al. 2002, supra).

While JAK1, JAK2 and TYK2 are expressed ubiquitously, JAK3 is reported to be preferably expressed in natural killer cells (NK) and non-resting T cells, suggesting a role in lymphoid activation (Kawamura, M., DW McVicar, et al. (1994). "Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes." Proc Natl Acad Sci USA 91 (14): 6374-8).

The immune and inflammatory responses stimulated by cytokines not only contribute to the defense of the normal host, they also play roles in the pathogenesis of diseases: Pathologies such as severe combined immunodeficiency (SCID) arise from hypoactivity and suppression of the immune system, and an overactive or inappropriate immune / inflammatory response contributes to the pathology of autoimmune diseases such as rheumatoid and psoriatic arthritis, asthma and systemic lupus erythematosus, as well as diseases such as scleroderma and osteoarthritis (Ortmann, RA, T. Cheng, et al. (2000). "Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation." Arthritis Res 2 (1): 16-32). In addition, syndromes with a mixed presentation of autoimmune disease and immunodeficiency are quite common (Candotti, F., L. Notarangelo, et al. (2002). "Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways." J Clin Invest 109 (10): 1261-9). Thus, therapeutic agents are typically aimed at increasing or suppressing immune and inflammatory pathways, as appropriate.

Deficiencies in the expression of members of the JAK family are associated with disease states. Jak1 - / - mice are delayed at birth, do not breastfeed and die in the perinatal period Rodig, SJ, MA Meraz, et al. (1998). "Disruption of the Jak1 gene demonstrates mandatory and nonredundant roles of the Jaks in cytokine-induced biologic responses." Cell 93 (3): 373-83). Jak2 mouse embryos - / - are anemic and

<figref>image2</figref>

<figref>image3</figref>

<figref>image4</figref>

<figref>image5</figref>

<figref>image6</figref>

<figref>image7</figref>

<figref>image8</figref>

<figref>image9</figref>

<figref>image10</figref>

<figref>image11</figref>

E05854854

07-05-2015

nuclear magnetic resonance spectroscopy (for example, 1H or 13C) infrared spectroscopy, spectrophotometry (for example, UV visible) or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

5 The compounds of the invention can be prepared according to numerous preparatory routes known in the literature. Exemplary synthetic methods for preparing compounds of the invention are provided in the following Schemes.

Scheme 1 shows an exemplary synthesis of compounds of the invention starting with pyrrolo [2,3b] pyridines 1-1 of which the N-oxo analog (1-2) is made by treatment with an oxidant such as m-CPBA. The N-oxide 1-2 can be halogenated with a halogenating agent such as MeSO2Cl, to form a 4-halo 1-3 compound (Y is halo as Cl). The 4-amino compounds of the invention (1-4) can be generated by treating 1-3 with an appropriate amine (NHR4R5), optionally in the presence of heat. In some situations, the 1-3 pyrrolo amine can be protected with a suitable amino protecting group before the reaction with NHR4R5, and the protecting group

fifteen amino can be removed after the reaction with NHR4R5.

<figref>image12</figref>

Scheme 2 provides an exemplary synthesis of compounds of the invention where R5 is piperidin-3-yl. A 4-chloro 2-1 compound (where the pyrrolo amine group can be optionally protected by an appropriate amino protecting group; in cases where the pyrrolo amine group is protected, the protective group can be removed at a later stage), can be treated with a 2-2 protected piperidine to form a compound of

Four. Five 4-piperidine 2-3. The protecting group on the N atom in the piperidine fraction of 2-3 can be removed by routine methods (for example hydrogenation in the presence of a Pd catalyst and HCl to remove the benzyl protecting group) to form a compound 2-4. The alkylation or acylation of the N atom in the piperidine fraction of 2-4 with a reagent such as R6-X, where X is a leaving group such as halo, hydroxyl, mesylate, tosylate, etc., provides a compound 2-5 of the invention. For example, R6-X may be a carboxylic acid, acid chloride, alkyl / aryl sulfonyl chloride, haloalkane, etc.

55

E05854854

07-05-2015

<figref>image13</figref>

The methods for preparing pyrrolo [2,3-d] pyrimidines according to the invention are presented in WO01 / 42246, WO 02/00661 and WO 03/48162.

Methods

35 The compounds of the invention can modulate the activity of one or more Janus kinases (JAKs). The term "modular" is intended to refer to an ability to increase or decrease the activity of one or more members of the JAK family of kinases. Therefore, the compounds of the invention can be used in methods for modulating a JAK by contacting the JAK with any one or more of the compounds or compositions described herein. In some embodiments, the compounds of the present invention may act as inhibitors of one or more JAKs. In some embodiments, the compounds of the present invention may act to stimulate the activity of one or more JAKs. In further embodiments, the compounds of the invention can be used to modulate the activity of a JAK in an individual in need of receptor modulation by administering a modulating amount of a compound of the invention.

Four. Five The JAKs to which the present compounds bind and / or modulate include any member of the JAK family. In some embodiments, the JAK is JAK1, JAK2, JAK3 or TYK2. In some embodiments, the JAK is JAK1 or JAK2. In some embodiments, the JAK is JAK2.

The compounds of the invention can be selective. "Selective Po 2" means that the compound binds with or inhibits a Jak with higher affinity or potency, respectively, compared to at least one other JAK. In some embodiments, the compounds of the invention are selective inhibitors of JAK1 or JAK2 over JAK3 and / or TYK2 In some embodiments, the compounds of the invention are selective inhibitors of JAK2 (eg, on JAK1, JAK3 and TYK2). Without wishing to be bound by theory, because JAK3 inhibitors can lead to immunosuppressive effects, a compound that is selective for JAK2 over JAK3 and is useful in

55 Cancer treatment (such as multiple myeloma, for example) may offer the additional advantage of having lower immunosuppressive side effects. The selectivity can be at least about 5 times, 10 times, at least about 20 times, at least about 50 times, at least about 100 times, at least about 200 times, at least about 500 times or at less about 1000 times. Selectivity can be measured by routine methods of the technique. In some embodiments, the selectivity can be tested in the Km of each enzyme. In some embodiments, the selectivity of the compounds of the invention for JAK2 over JAK3 can be determined by the concentration of cellular ATP.

Another aspect of the present invention corresponds to the compounds for use in methods for treating a disease or disorder associated with JAK in an individual (eg patient) by administering to the individual in need of said treatment a therapeutically effective amount or dose of a compound. of the present

<figref>image14</figref>

<figref>image15</figref>

<figref>image16</figref>

<figref>image17</figref>

<figref>image18</figref>

<figref>image19</figref>

E05854854

07-05-2015

5

<figref>image20</figref>

A degassed mixture of (3R, 4R) -1-benzyl-N, 4-dimethylpiperidin-3-amine (0.210 g, 0.000962 mol), 4

chloro-1- [2- (trimethylsilyl) ethoxy] methyl-1H-pyrrolo [2,3-b] pyridine (0.29 g, 0.0010 mol),

tris (dibenzylideneaketone) dipaladium (0) (0.088 g, 0.00096 mol), 0.049 M tri-tert-butylphosphine in toluene (1.0 ml) and

fifteen sodium tert-butoxide (0.139 g, 0.00144 mol) in toluene (3ml, 0.03 mol) was heated at 70 ° C for 5 hours. After the reaction mixture was cooled to room temperature (rt), ethyl acetate and water were added. The resulting suspension was filtered. The aqueous phase was removed and the remaining organic phase was washed with saturated NaCl, dried and concentrated in vacuo to give 540 mg of orange oil. The crude product was chromatographed using 35% ethyl acetate / hex to give 280 mg of orange oil (~ 1: 1 two isomers). The mixture was chromatographed again with 35% ethyl acetate / hex several times to remove 44 mg of the highest R1 material. 1H NMR (400 MHz, CDCl3): δ 8.15 (1H, d); 7.38 (5H, m); 7.18 (1H, d); 6.6 (1H, d); 6.3 (1H, d); 5.7 (2H, s); 4.58 (1H, t); 3.6 (4H, m); 3.38 (3H, s); 2.86 (1H, br); 2.79 (1H, br); 2.6 (1H, br); 2.55 (1H, br); 2.4 (1H, br); 1.95 (1H, br); 1.77 (1H, br); 1.02 (3H, d); 0.99 (2H, t); 0 (9H, s). MS (M + H) +: 465.

25

Step 3: N - [(3R, 4R) -1-benzyl-4-methylpiperidin-3-yl] -N-methyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine

35

<figref>image21</figref>

A solution of N - [(3R, 4R) -1-benzyl-4-methylpiperidin-3-yl] -N-methyl-1- [2 (trimethylsilyl) ethoxy] methyl-N- (1 H -pyrrolo [1] 2,3-b] pyridin-4-yl) -amine (0.065 g, 0.00014 mol) in trifluoroacetic acid (0.6 ml, 0.008 mol) and methylene chloride (3 ml, 0.05 mol). The volume of the solvent was reduced by roto-vap 3x subjected to azeotropic with MeOH. The resulting orange oil was stirred in methanol (1.5 ml, 0.037 mol) and 1.00 M sodium hydroxide in water (0.5 ml) overnight. The solvents were removed in vacuo and the remaining solid was stirred in ethyl acetate and water. The organic phase was washed with saturated NaCl and the solvent was removed in vacuo to give 37 mg of a

Four. Five orange oil 1H NMR (400 MHz, CDCl3): δ 8.0 (1H, d); 7.38 (5H, m); 7.1 (1H, d); 6.75 (1H, d); 6.2 (1H, d); 4.58 (1H, t); 3.55 (2H, m); 3.3 (3H, s); 2.8 (1H, br); 2.7 (1H, br); 2.55 (1H, br); 2.45 (1H, br); 2.32 (1H, br); 1.9 (1H, br); 1.65 (1H, br); 1.02 (3H, d). MS (M + H) +: 335.

Step 4: N-methyl-N - [(3R, 4R) -4-methylpiperidin-3-yl] -N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine

55

<figref>image22</figref>

<figref>image23</figref>

E05854854

07-05-2015

Table 1

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>3 </dt><dd><figref>image24</figref>N-methyl-N - [(3R, 4R) -4-methyl1- (phenylsulfonyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 385.2 </dd></dl>

<dl><dt>4 </dt><dd>N - [(3R, 4R) -1- (methoxyacetyl) -4-methylpiperidin-3-yl] N-methyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 316.2 </dd></dl>

<dl><dt>5 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] -N-phenylpiperidine-1-carboxamide 364.2 </dd></dl>

<dl><dt>6 </dt><dd>(3R, 4R) -N-benzyl-4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 378.2 </dd></dl>

<dl><dt>7 </dt><dd>(3R, 4R) -N-ethyl-4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 316.2 </dd></dl>

<dl><dt>8 </dt><dd><figref>image25</figref>(3R, 4R) -N-Isopropyl-4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 330.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>9 </dt><dd>N - [(3R, 4R) -1-isobutyryl-4-methylpiperidin-3-yl] -N-methylN- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 315.2 </dd></dl>

<dl><dt>10 </dt><dd><figref>image26</figref>N-methyl-N - [(3R, 4R) -4-methyl-1- (morpholin-4ylcarbonyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 358.2 </dd></dl>

<dl><dt>11 </dt><dd>N - [(3R, 4R) -1-acetyl-4-methylpiperidin-3-yl] -Nmethyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 287.2 </dd></dl>

<dl><dt>12 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl-1- (3-methylbutanoyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 329.2 </dd></dl>

<dl><dt>13 </dt><dd><figref>image27</figref>N - [(3R, 4R) -1-benzoyl-4-methylpiperidin-3-yl] -Nmethyl-N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine 349.2 </dd></dl>

<dl><dt>14 </dt><dd>(3R, 4R) -N, N, 4-trimethyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidine-1-carboxamide 316.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>15 </dt><dd>4 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) benzonitrile 374.2 </dd></dl>

<dl><dt>16 </dt><dd>N - [(3R, 4R) -1- (cyclopropylcarbonyl) -4-methylpiperidin-3-yl] -N-methyl-N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 313.2 </dd></dl>

<dl><dt>17 </dt><dd>N - [(3R, 4R) -1-isonicotinoyl-4-methylpiperidin-3-yl] -Nmethyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 350.2 </dd></dl>

<dl><dt>18 </dt><dd><figref>image28</figref>N - {(3R, 4R) -1 - [(1-acetylpiperidin-4-yl) carbonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4- il) -amina 398.2 </dd></dl>

<dl><dt>19 </dt><dd>Phenyl (3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidine-1-carboxylate 365.2 </dd></dl>

<dl><dt>20 </dt><dd><figref>image29</figref>Methyl (3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidine-1-carboxylate 303.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>21 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl1- (trifluoroacetyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 341.2 </dd></dl>

<dl><dt>22 </dt><dd><figref>image30</figref>N - [(3R, 4R) -1- (2-furoyl) 4-methylpiperidin-3-yl] -Nmethyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 339.2 </dd></dl>

<dl><dt>23 </dt><dd>(3R, 4R) -N- (4-cyanophenyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 389.2 </dd></dl>

<dl><dt>24 </dt><dd><figref>image31</figref>(3R, 4R) -N- (3-cyanophenyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 389.2 </dd></dl>

<dl><dt>25 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] -N- (2-phenylethyl) piperidine-1-carboxamide 392.2 </dd></dl>

<dl><dt>26 </dt><dd><figref>image32</figref>(3R, 4R) -N- (2-Furylmethyl) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 368.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>27 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl1- (propylsulfonyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 351.2 </dd></dl>

<dl><dt>28 </dt><dd><figref>image33</figref>N - [(3R, 4R) -1- (isopropylsulfonyl) -4-methylpiperidin-3yl] -N-methyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 351.2 </dd></dl>

<dl><dt>29 </dt><dd>4 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} sulfonyl) benzonitrile 410.2 </dd></dl>

<dl><dt>30 </dt><dd>2 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} sulfonyl) benzonitrile 410.2 </dd></dl>

<dl><dt>31 </dt><dd><figref>image34</figref>N-methyl-N - [(3R, 4R) -4-methyl1- (methylsulfonyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 323.2 </dd></dl>

<dl><dt>32 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(trifluoromethyl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin-4-yl) - amine 377.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>33 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl-1- (pyridin-3-sulfonyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 386.2 </dd></dl>

<dl><dt>34 </dt><dd>2-fluoro-5 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} sulfonyl) benzonitrile 428.2 </dd></dl>

<dl><dt>35 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl-1- (3-pyridin-3ylpropanoyl) piperidin-3-yl] -N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 378.2 </dd></dl>

<dl><dt>36 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl-1- (3,3,3trifluoropropanoyl) piperidin-3-yl] -N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 355.2 </dd></dl>

<dl><dt>37 </dt><dd>N-methyl-N - [(3R, 4R) -4-methyl-1- (tetrahydrofuran-2-carbonyl) piperidin-3-yl] -N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 343.2 </dd></dl>

<dl><dt>38 </dt><dd><figref>image35</figref>(2R) -1 - {(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} -1-oxopropan-2ol 317.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>39 </dt><dd>(2S) -1 - {(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} -1-oxopropan-2 -ol 317.2 </dd></dl>

<dl><dt>40 </dt><dd><figref>image36</figref>N-methyl-N - [(3R, 4R) -4-methyl-1- (3phenylpropanoyl) piperidin-3-yl] -N- (1 H -pyrrolo [2,3b] pyridin-4-yl) -amine 377.2 </dd></dl>

<dl><dt>41 </dt><dd>(3R, 4R) -N- (4-cyanophenyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carbothioamide 405.2 </dd></dl>

<dl><dt>42 </dt><dd><figref>image37</figref>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(5-methylisoxazol-4yl) sulfonyl] piperidin-3-yl} -N- (1H-pyrrolo [2,3-b] pyridin4 -il) -amine 390.2 </dd></dl>

<dl><dt>43 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(1-methyl-1Himidazol-4-yl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b ] pyridin-4-yl) -amine 389.2 </dd></dl>

<dl><dt>44 </dt><dd>N - {(3R, 4R) -1 - [(3,5-dimethylisoxazol-4-yl) carbonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridine- 4-yl) -amine 368.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>45 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] -N-2-thienylpiperidine-1-carboxamide 370.2 </dd></dl>

<dl><dt>46 </dt><dd>N - [(3R, 4R) -1- (isoxazol-5-ylcarbonyl) -4me tilpiperidin-3-yl] -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 340.2 </dd></dl>

<dl><dt>47 </dt><dd>N - {(3R, 4R) -1 - [(1,2-dimethyl-1H-imidazol-4yl) sulfonyl] -4-methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3- b] pyridin-4-yl) -amine 403.2 </dd></dl>

<dl><dt>48 </dt><dd><figref>image38</figref>N- [4-methyl-5 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} sulfonyl) -1 , 3-thiazol-2-yl] acetamide 463.2 </dd></dl>

<dl><dt>49 </dt><dd><figref>image39</figref>N - {(3R, 4R) -1 - [(2,4-dimethyl-1,3-thiazol-5yl) sulfonyl] -4-methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2, 3-b] pyridin-4-yl) -amine 420.2 </dd></dl>

<dl><dt>50 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(1,3,5-trimethyl-1Hpyrazol-4-yl) sulfonyl] piperidin-3-yl} -N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine 417.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

65

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>51 </dt><dd>N - {(3R, 4R) -1 - [(3,5-dimethylisoxazol-4-yl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridine- 4-yl) -amine 404.2 </dd></dl>

<dl><dt>52 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(pyridin-4ylmethyl) sulfonyl] piperidin-3-yl} -N- (1H-pyrrolo [2,3b] pyridin-4-yl )-amine 400.2 </dd></dl>

<dl><dt>53 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(pyridin-3ylmethyl) sulfonyl] piperidin-3-yl} -N- (1H-pyrrolo [2,3b] pyridin-4-yl )-amine 400.2 </dd></dl>

<dl><dt>54 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(pyridin-2ylmethyl) sulfonyl] piperidin-3-yl} -N- (1H-pyrrolo [2,3b] pyridin-4-yl )-amine 400.2 </dd></dl>

<dl><dt>55 </dt><dd>4 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} sulfonyl) benzonitrile 410.2 </dd></dl>

<dl><dt>56 </dt><dd>(3R, 4R) -N- (4-cyanophenyl) -N, 4-dimethyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 403.2 </dd></dl>

<dl><dt>57 </dt><dd><figref>image40</figref>(3R, 4R) -N- (4-cyanophenyl) -N-ethyl-4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 417.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

65

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>58 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] -N-1,3-thiazol-2-ylpiperidine-1-carboxamide 371.2 </dd></dl>

<dl><dt>59 </dt><dd>(3R, 4R) -4-methyl-N- (3-methylisoxazol-5-yl) -3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 369.2 </dd></dl>

<dl><dt>60 </dt><dd>3-Chloro-4 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} sulfonyl) benzonitrile 444.1 </dd></dl>

<dl><dt>61 </dt><dd><figref>image41</figref>(3R, 4R) -4-methyl-N- (5-methylisoxazol-3-yl) -3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 369.2 </dd></dl>

<dl><dt>62 </dt><dd>(3R, 4R) -N-Isoxazol-3-yl-4-methyl-3- [methyl (1 H -pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 355.2 </dd></dl>

<dl><dt>63 </dt><dd><figref>image42</figref>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(5-pyridin-3-yl-2-thienyl) sulfonyl] piperidin-3-yl} -N- (1 H -pyrrolo [2,3b ] pyridin-4-yl) -amine 468.2 </dd></dl>

<dl><dt>64 </dt><dd><figref>image43</figref>(3R, 4R) -N- (3-Cyano-2-thienyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 395.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>65 </dt><dd>(3R, 4R) -N-1,3-benzothiazol-2-yl-4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 421.2 </dd></dl>

<dl><dt>66 </dt><dd>N - [(3R, 4R) -1- (2,3-dihydro-1H-indole-1-ylcarbonyl) -4-methylpiperidin-3-yl] -N-methyl-N- (1H-pyrrolo [2,3-b ] pyridin4-yl) -amine 390.2 </dd></dl>

<dl><dt>67 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(methylthio) acetyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin-4-yl) - amine 333.2 </dd></dl>

<dl><dt>68 </dt><dd><figref>image44</figref>(3R, 4R) -N- (4,5-dihydro-1,3-thiazol-2-yl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 373.2 </dd></dl>

<dl><dt>69 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] -N- (1,3-thiazol-2-methylmethyl) piperidine-1-carboxamide 385.2 </dd></dl>

<dl><dt>70 </dt><dd>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) piperidine-4-carbonitrile 381.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>71 </dt><dd>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) piperidine-3-carbonitrile 381.2 </dd></dl>

<dl><dt>72 </dt><dd><figref>image45</figref>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 367.2 </dd></dl>

<dl><dt>73 </dt><dd>(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin4-yl) amino] -N- (3-thienylmethyl) piperidine-1-carboxamide 384.2 </dd></dl>

<dl><dt>74 </dt><dd><figref>image46</figref>(3R, 4R) -N- (2-benzothien-1-ylmethyl) -4-methyl-3- [methyl (1 H -pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 434.2 </dd></dl>

<dl><dt>75 </dt><dd>(3R, 4R) -N- (1,3-benzothiazol-2-ylmethyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 435.2 </dd></dl>

<dl><dt>76 </dt><dd><figref>image47</figref>N - [(3R, 4R) -1- (3-furylacetyl) -4-methylpiperidin-3-yl] N-methyl-N- (1 H -pyrrolo [2,3-b] pyridin-4-yl) -amine 353.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>77 </dt><dd>3- (2 - {(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} -2-oxoethyl) -1 , 3-thiazolidine-2,4-dione 402.2 </dd></dl>

<dl><dt>78 </dt><dd><figref>image48</figref>3- (2 - {(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} -2-oxoethyl) -1 , 3benzothiazol-2 (3H) -one 436.2 </dd></dl>

<dl><dt>79 </dt><dd>(3R, 4R) -N- [5- (cyanomethyl) -4,5-dihydro, -1,3-thiazol2-yl] -3- [methyl- (1H-pyrrolo [2,3-b] pyridin-4 -yl) amino] -4methyl-piperidine-1-carboxamide 412.2 </dd></dl>

<dl><dt>80 </dt><dd><figref>image49</figref>(3S) -1 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 367.2 </dd></dl>

<dl><dt>81 </dt><dd>(3R) -1 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 367.2 </dd></dl>

<dl><dt>82 </dt><dd><figref>image50</figref>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} carbonyl) -4-phenylpiperidine-4-carbonitrile 457.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>83 </dt><dd>N-methyl-N - ((3R, 4R) -4-methyl-1 {[3- (trifluoromethyl) pyrrolidin-1-yl] carbonyl} piperidin-3-yl) -N- (1H-pyrrolo [2,3b] pyridin -4-yl) -amine 410.2 </dd></dl>

<dl><dt>84 </dt><dd>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) azetidine-3-carbonitrile 353.2 </dd></dl>

<dl><dt>85 </dt><dd>4-methyl-1 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 381.2 </dd></dl>

<dl><dt>86 </dt><dd><figref>image51</figref>1 - ({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3,4-dicarbonitrile 392.2 </dd></dl>

<dl><dt>87 </dt><dd>3-methyl-1 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 381.2 </dd></dl>

<dl><dt>88 </dt><dd><figref>image52</figref>(3R, 4R) -N- (2-cyanoethyl) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-carboxamide 341.2 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>89 </dt><dd>4-methoxy-1 - ({(3R, 4R) -4-methyl-3- [methyl (1Hpyrrolo [2,3-b] pyridin-4-yl) amino] piperidin-1yl} carbonyl) pyrrolidine-3-carbonitrile 397.2 </dd></dl>

<dl><dt>90 </dt><dd><figref>image53</figref>N - {(3R, 4R) -1 - [(2R) -2-aminopropanoyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) - amine 316.1 </dd></dl>

<dl><dt>91 </dt><dd><figref>image54</figref>N - [(3R, 4R) -1- (aminoacetyl) -4-methylpiperidin-3yl] -N-methyl-N- (1H-pyrrolo [2,3-b] pyridin-4yl) -amine 302.1 </dd></dl>

<dl><dt>92 </dt><dd>1- (2 - {(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3b] pyridin-4-yl) amino] piperidin-1-yl} -2oxoethyl) piperidine-4- carbonitrile 395.1 </dd></dl>

<dl><dt>93 </dt><dd><figref>image55</figref>N-methyl-N - [(3R, 4R) -4-methyl-1- (1,3-thiazol-4ylcarbonyl) piperidin-3-yl] -N- (1H-pyrrolo [2,3b] pyridin-4- il) -amine bis (trifluoroacetate) 356.1 </dd></dl>

<dl><dt>97 </dt><dd><figref>image56</figref>Methyl 3 - [({(3R, 4R) -4-methyl-3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) amino] piperidine-1-yl} carbonyl) -amino] benzoate 422.1 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>98 </dt><dd>(3R, 4R) -N- (4-trifluoromethoxyphenyl) -4-methyl-3 [methyl- (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 448.1 </dd></dl>

<dl><dt>99 </dt><dd>(3R, 4R) -N- (4-fluorophenyl) -4-methyl-3 [methyl- (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 382.1 </dd></dl>

<dl><dt>100 </dt><dd>(3R, 4R) -N- (3-fluorophenyl) -4-methyl-3 [methyl- (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 382.1 </dd></dl>

<dl><dt>101 </dt><dd><figref>image57</figref>(3R, 4R) -N- (2-fluorophenyl) -4-methyl-3 [methyl- (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 382.1 </dd></dl>

<dl><dt>102 </dt><dd>(3R, 4R) -N- (4-trifluoromethylphenyl) -4-methyl-3 [methyl- (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 432.1 </dd></dl>

<dl><dt>103 </dt><dd>(3R, 4R) -N- (2-methoxyphenyl) -4-methyl-3 [methyl (1H-pyrrolo [2,3-b] pyridin-4yl) amino] piperidine-1-carboxamide 394.1 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>104 </dt><dd>(3R, 4R) -4-methyl-N- (4-methylphenyl) -3- [methyl (1H-pyrrolo [2,3-b] pyridin-4-yl) -amino] piperidine-1-carboxamide 378.1 </dd></dl>

<dl><dt>105 </dt><dd><figref>image58</figref>N-methyl-N - {(3R, 4R) -4-methyl-1- [4- (pyridin-2-yloxy) phenyl] sulfonyl-piperidin-3-yl} -N- (1H-pyrrolo [2,3-b ] pyridin-4-yl) -amine 478.1 </dd></dl>

<dl><dt>106 </dt><dd><figref>image59</figref>N-methyl-N - {(3R, 4R) -4-methyl-1- [4- (1,3-oxazol-5yl) phenyl] sulfonyl-piperidin-3-yl} -N- (1H-pyrrolo [2 , 3b] pyridin-4-yl) -amine 452.1 </dd></dl>

<dl><dt>107 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1- [5- (1,3-oxazol-5yl) thienyl] sulfonyl-piperidin-3-yl} -N- (1H-pyrrolo [2 , 3b] pyridin-4-yl) -amine 458.1 </dd></dl>

<dl><dt>108 </dt><dd><figref>image60</figref>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(6-phenoxypyridin-3-yl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin -4-yl) -amine 478.1 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>109 </dt><dd>N - {(3R, 4R) -1 - [(2,6-dichlorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 453.1 </dd></dl>

<dl><dt>110 </dt><dd><figref>image61</figref>N - {(3R, 4R) -1 - [(4-fluorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 403.1 </dd></dl>

<dl><dt>111 </dt><dd><figref>image62</figref>N - {(3R, 4R) -1 - [(3-fluorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 403.1 </dd></dl>

<dl><dt>112 </dt><dd><figref>image63</figref>N - {(3R, 4R) -1 - [(2-fluorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 403.1 </dd></dl>

<dl><dt>113 </dt><dd>N - {(3R, 4R) -4-methyl1- [4- (trifluoromethyl) phenyl] sulfonyl-piperidin-3-yl} N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine 453.1 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

55

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>114 </dt><dd>N - {(3R, 4R) -4-methyl1- [3- (trifluoromethyl) phenyl] sulfonyl-piperidin-3-yl} N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine 453.1 </dd></dl>

<dl><dt>115 </dt><dd>N - {(3R, 4R) -4-methyl1- [2- (trifluoromethyl) phenyl] sulfonyl-piperidin-3-yl} N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -amine 453.1 </dd></dl>

<dl><dt>116 </dt><dd><figref>image64</figref>N - {(3R, 4R) -1 - [(4-methoxyphenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 415.1 </dd></dl>

<dl><dt>117 </dt><dd><figref>image65</figref>N - {(3R, 4R) -1 - [(3-methoxyphenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 415.1 </dd></dl>

<dl><dt>118 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(4methylphenyl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin-4-yl) - amine 399.1 </dd></dl>

E05854854

07-05-2015

(continued)

5

15

25

35

45

<dl><dt>Nº of Ex </dt><dd>Structure First name (M + 1) </dd></dl>

<dl><dt>119 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(3methylphenyl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin-4-yl) - amine 399.1 </dd></dl>

<dl><dt>120 </dt><dd>N-methyl-N - {(3R, 4R) -4-methyl-1 - [(2methylphenyl) sulfonyl] piperidin-3-yl} -N- (1Hpyrrolo [2,3-b] pyridin-4-yl) - amine 399.1 </dd></dl>

<dl><dt>121 </dt><dd><figref>image66</figref>N - {(3R, 4R) -1 - [(4-chlorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 419.1 </dd></dl>

<dl><dt>122 </dt><dd>N - {(3R, 4R) -1 - [(3-chlorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 419.1 </dd></dl>

<dl><dt>123 </dt><dd>N - {(3R, 4R) -1 - [(2-chlorophenyl) sulfonyl] -4methylpiperidin-3-yl} -N-methyl-N- (1H-pyrrolo [2,3b] pyridin-4-yl) -amine 419.1 </dd></dl>

55

Example A

JAK in vitro test

The compounds herein are tested for inhibitory activity of the Jak targets according to the following in vitro assay described in Park et al., Analytical Biochemistry 1999, 269, 94-104. The catalytic domains of human Jak1 (aa 837-1142), Jak2 (aa 828-1132) and Jak3 (aa 781-1124) with an N-terminal His tag were expressed using baculovirus in insect cells and were purified. The catalytic activity of JAK1, JAK2 or JAK3 was tested by measuring the phosphorylation of a biotinylated peptide. The phosphorylated peptide was detected by fluorescence

65 resolved in homogeneous time (HTRF). The IC50 of the compounds for each kinase in the

<figref>image67</figref>

<figref>image68</figref>